New narcolepsy treatments are being tested in the clinic, and recently, some of them have made promising strides. How far ...

Q2 2025 Earnings Call Transcript July 29, 2025 Alkermes plc beats earnings expectations. Reported EPS is $0.517, expectations ...

A recent study published in Current Pharmaceutical Analysis explores the activity of the TNF-α system in patients with various brain disorders and during psychopharmacological treatment. The research ...

Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts ...

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Long term use of once-nightly sodium oxybate is well-tolerated among patients with narcolepsy type 1 or 2 with primarily mild adverse reactions.

Narcolepsy in dogs is pretty rare, but it does happen, especially in certain breeds. It’s a neurological disorder that ...